Elhalag_2024_Ann.Med.Surg.(Lond)_86_2105

Reference

Title : The risk of bone fractures in dementia patients receiving acetylcholinesterase inhibitors: a meta-analysis - Elhalag_2024_Ann.Med.Surg.(Lond)_86_2105
Author(s) : Elhalag RH , Chebl P , Bayoumy NM , Hassan N , Hagar H , Abowafia M , Gaber H , Belal MM , Shah J , Motawea KR
Ref : Ann Med Surg (Lond) , 86 :2105 , 2024
Abstract :

AIM: The authors aimed to conduct a meta-analysis to determine if acetylcholinesterase inhibitors may pose a direct threat, increasing the incidence of fractures in dementia patients. METHODS: PubMed, Scopus, and Cochrane Library were searched. Inclusion criteria were any original studies that demonstrated the link between acetylcholinesterase inhibitors and the incidence of fracture in patients with dementia. RevMan(5.4) was used. RESULTS: Seven observational studies were included. The total number of patients included in the acetylcholinesterase inhibitors group is 274 332 and 290 347 in the control group. The pooled analysis showed that the risk of bone fracture was not statistically different between dementia patients who received acetylcholinesterase inhibitors and those who did not receive them (odds ratio=1.44, CI 0.95, 2.19, P=0.09). Subgroup analysis showed no statistically significant difference between dementia patients who took acetylcholinesterase inhibitors, and those who didn't take acetylcholinesterase inhibitors in those more than or equal to 80 years old and those less than 80 years old (P=0.44) and (P=0.34) respectively. However, our results showed a statistically significant association between dementia patients who received acetylcholinesterase inhibitors and decreased fracture risk in those receiving the treatment for more than or less than 2 years (risk ratio=0.48, CI= 0.45, 0.51, P<0.00001) and (risk ratio=0.84, CI 0.70, 0.99, P=0.04), respectively. CONCLUSION: Our study revealed no role for acetylcholinesterase inhibitors in increasing the risk of fracture compared with controls. Hence, based on our analysis, they might have a protective role against fracture when used for long periods considering their positive action on bone growth and development. Therefore, Acetylcholinesterase inhibitors could be considered a safe option for improving cognitive functions in elderly demented patients without carrying any additional risks.

PubMedSearch : Elhalag_2024_Ann.Med.Surg.(Lond)_86_2105
PubMedID: 38576949

Related information

Citations formats

Elhalag RH, Chebl P, Bayoumy NM, Hassan N, Hagar H, Abowafia M, Gaber H, Belal MM, Shah J, Motawea KR (2024)
The risk of bone fractures in dementia patients receiving acetylcholinesterase inhibitors: a meta-analysis
Ann Med Surg (Lond) 86 :2105

Elhalag RH, Chebl P, Bayoumy NM, Hassan N, Hagar H, Abowafia M, Gaber H, Belal MM, Shah J, Motawea KR (2024)
Ann Med Surg (Lond) 86 :2105